| Displaying page 1 of 4 [1] 2 3 4 | Next page > |
Displaying all Cardiovascular / Renal Health articles
- Dec 11Treatment with 'Januvia'® (Sitagliptin) associated with fewer major cardiovascular events in people with type 2 diabetes compared with a sulphonylureaA new pooled analysis presented today at the International Diabetes Federation (IDF) 21st World Diabetes Congress has demonstrated that people with type 2 diabetes taking 'Januvia' (sitagliptin) experienced a lower incidence of major cardiovascular (CV) events (MACE)* compared to those treated with a sulphonylurea (SU).1
- Nov 11Campaign targets 'hypo' driversDiabetics who experience low blood sugar attacks while driving are the focus of a new health campaign launched by TREND, a diabetes nursing group together with the Automobile Association (AA) and MSD Diabetes.
- Nov 11First 3-in-1 combination therapy for essential hypertension launches in UKSevikar HCT®▼ simplifies treatment and could improve the management of hypertension
- Nov 11Panasonic's CardioHealth Station Improves Patient Outcomes Through Early Diagnosis in Primary CarePanasonic have announced the European availability of its innovative ultrasound tool for personalized preventive medicine, the CardioHealth Station.
- Nov 11NICE consults on new draft guidance on preventing type 2 diabetesNICE has today (Wednesday 9 November) opened a consultation on new draft guidance on identifying people at high risk of developing type 2 diabetes and the provision of clinically and cost effective interventions to help reduce the risk or delay the onset of the condition.
- Nov 11Care failings put 1 in 4 people with diabetes at risk of amputationOne in four people (25 per cent) with diabetes in the UK could be at risk of amputation because they have not received a foot check in the last year, according to a new survey by Diabetes UK.
- Nov 11NICE approves BRILIQUE™▼ (ticagrelor) in patients who have had a heart attack or an episode of unstable anginaPCTs now have three months to make this life-saving treatment available as an option for physicians and their patients.
- Sept 11BRILIQUE™ (ticagrelor) receives final draft recommendation from NICE for use in patients who have had a heart attack or an episode of unstable anginaAstraZeneca has announced that the National Institute for Health and Clinical Excellence (NICE) has recommended the use of the novel antiplatelet medicine, Brilique™ (ticagrelor) by the National Health Service (NHS) in England and Wales1,2.
- Aug 11New NICE guideline will radically change how high blood pressure is diagnosedNICE has published an updated guideline on the diagnosis and treatment of high blood pressure (hypertension).
Exenatide for prolonged release delivers glycaemic control in a single weekly dose
| Displaying page 1 of 4 [1] 2 3 4 | Next page > |


